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Purpose/Objective: To present and analyze clinical results 
obtained with an in house two-dimensional EPID-based in vivo 
dose reconstruction algorithm on head and neck cancers 
treated by intensity-modulated radiation therapy (IMRT). 
Materials and Methods: Our modela enables two dimensional 
dose distributions inside a patient to be reconstructed from 
portal images. Doses are backprojected inside patients in the 
isocenter plan perpendicular to the beam axis. The algorithm 
was developed in Matlab™ V.R2012b and was created for an 
aS-500/2 irradiated by a 6 MV photon beam energy on a 
Clinac iX (Varian Medical System™, Palo Alto, CA, USA). 
3 head & neck IMRT treatment plan were used in this work 
which represents 18 different dose reconstructions. For each 
field, the dose calculated from EPID signal was compared to 
the dose calculated with our treatment planning system 
(Eclipse™ v.10) using the γ-evaluation method with 5% or 3% 
of the maximum dose delivered as dose difference criterion 
and 3 mm as distance-to-agreement criterion.  
Results: The average of points satisfying the γ-criteria is 
equal to 96.1 % ± 1.7 % with a 5% dose difference criterion 
and 92.5 % ± 1.9 % with a 3% dose difference criterion for the 
18 fields studied. The analysis of gamma distribution showed 
good agreement between reconstructed and calculated 
doses. Major differences were observed for pixels located in 
front of heterogeneities (air / bones / prosthesis). 
Conclusions: Results obtained here confirm that the 
developed algorithm is usable in clinical routine to perform 
in vivo dosimetry on head and neck cancers treated by IMRT. 
In the future, heterogeneity correction should be developed 
in order to obtain a powerful IMRT quality assurance tool. 
 
a J.Camilleri et al. '2D/3D EPID-based in-vivo dosimetry: 
Preliminary results'. 33th Annual meeting of the European 
Society of Therapeutic Radiology and Oncology (ESTRO), 04-
08 Avril 2014, Vienna (Austria). In: Radiotherapy and 
Oncology, Volume 103, Supplement 1, Pages S588.  
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Purpose/Objective: The objective of the R&D project is to 
develop an innovative mobile electron accelerator for IOERT. 
This report describes the progress of the project, its current 
status and future plans. 
Materials and Methods: The work was divided into two major 
milestones. The first objective was to develop a machine 
which key functionalities are an electron beam with energy 
from 4 to 12 MeV and a robotic manipulator with significant 
range of movement. A demonstrator machine was built from 
scratch at National Centre for Nuclear Research (NCBJ). The 
scope of work of this project phase (2008-2014) included 
beam dynamics modeling, Monte Carlo modeling, mechanical 
construction and electrical schemes, as well as development 
of a control system.  
The second project phase started at the beginning of 2014, 
and aimed at preparing a functional prototype of the 
complex system that emphasizes optimal ease of use in 
clinical environment. This phase is being carried out by a 
consortium of NCBJ, the Greater Poland Cancer Centre 
(clinical experts in IOERT) and two private companies that 
will be responsible for production of the new IOERT machine. 
Results: Beam characteristics: Most probable energy on 
phantom surface Ep0 – 12,21 MeV with depth of 90% isodose – 
33,70 mm; symmetry for each energy (4, 6, 9, 12 MeV) and 
each applicator size (3, 5, 10, 12 cm) - less than 102%. 
Mechanical parameters: the demonstrator device consists of 
an accelerator that is mounted on a robotic manipulator with 
six degrees of freedom. The manipulator consists of a trolley, 
pillar, crane and treatment head (Fig. 1). The trolley can 
move forward and backward, and turn left and right, the 
pillar can rotate the whole accelerator ± 90°. The crane 
holds the treatment head at its front end and microwave 
components at its rear. Crane tilt ranges from +30° to -20° 
with rotation range of ±45° and applies to the head mounted 
on the crane. The treatment head holds the accelerating 




Fig. 1: Device overview 
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In the course of our work four (4) patent applications were 
filed. 1) Electromedical device for intra operative radiation 
therapy by the means of ionizing radiation with energy higher 
than 9 MeV. 2) Electron irradiation head position regulation 
system of electromedical device for intra operative radiation 
therapy. 3) Electron beam forming system in treatment head 
of the mobile intra operative accelerator. 4) Electromedical 
device for intra operative radiation therapy with electronic 
control of ionization irradiation beam placement. 
Applications 1-3 have been granted a patent, application 4 is 
still pending. 
Conclusions: The IntraLine accelerator meets all of the 
objectives set for the demonstrator. However, future clinical 
application of this device may possibly require new 
mechanical and electrical schemes aiming at minimizing the 
device’s size and weight. Current work also focuses on the 
device’s motion support control system, as well as its 
treatment planning system. 
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Purpose/Objective: A 4D detector array (ArcCHECK, Sun 
Nuclear) has been developed specifically for rotational 
delivery QA and dosimetry. The purpose of this study was to 
evaluate the feasibility of the ArcCHECK as a patient specific 
QA device for different rotational treatment techniques. We 
report the preliminary results of the evaluation and discuss 
the determination of clinically relevant acceptance criteria. 
Materials and Methods: The ArcCHECK device is a cylindrical 
water-equivalent phantom (PMMA) with a three-dimensional 
array (21 cm diameter and length) of 1386 diode detectors 
arranged in a spiral pattern at depth 2.9 cm with 10 mm 
sensor spacing.. The proprietary SNC Patient software is used 
to compare the device measured planar dose distribution to 
that calculated by the TPS.  
We analyzed 40 treatment plans: 19 Dynamic Conformal Arc 
Therapy (DCAT) treatment plans for stereotactic 
radiotherapy of brain tumors, 11 Static Conformal Arc 
Therapy (SCAT) treatment plans for stereotactic radiotherapy 
of lung tumors and 10 Volumetric Modulated Arc Therapy 
(VMAT) treatment plans for different treatment sites (5 lung, 
3 head & neck, 1 liver and 1 head). The DCAT plans were 
constructed and calculated using the iPlan 3.0 TPS while the 
Oncentra Masterplan 4.3 TPS was used for the other plans. All 
the patient plans were recalculated for the ArcCHECK 
phantom geometry. For the DCAT plans a Monte Carlo 
algorithm was used, while a Collapsed Cone algorithm was 
used for the SCAT and VMAT plans. 
All measurements were carried out with 6 MV photon beams 
on a Varian TrueBeam STx linear accelerator using the 
ArcCHECK phantom with a solid homogenous PMMA insert. 
The pass rate of the g index was used to compare the 
measured and the calculated dose distribution. We used 
absolute dose mode and local dose difference normalization 
for the comparison as well as the minimum dose threshold 
equal to 10%. Two levels of acceptance criteria were tested 
for the comparison: 3%/3mm and 2%/2mm. 
Results: The measurements performed in the course of 
approximately 7 weeks showed a stable performance of the 
ArcCHECK device. Average g-passing rates for all treatment 
plans, including the passing rate intervals, are shown in Table 
1. Differences in passing rates between the DCAT, SCAT and 
VMAT plans are all statistically significant (p < 0.05) except 




Conclusions: In general the ArcCHECK device showed to be a 
convenient and robust tool for pre-treatment QA which is 
easy to use and handle. However we found that in order to 
sharpen the QA acceptance criteria and become more 
sensitive to the clinically relevant dose differences, it 
requires tailoring which takes into account beam delivery 
technique as well as 3D dose distribution.  
Further work is ongoing to include in the QA routines 3DVH 
comparison and the possibility to estimate the dose 
distribution in the patient. 
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Purpose/Objective: To compare three 2D-arrays of 
detectors, which have different distances between detectors 
and chamber sizes, used to verify SBRT treatments with 
Octavius 4D. 
Materials and Methods: Ten SBRT treatments of different 
locations were selected (including lung, liver, vertebra and 
nose) for the study. In one of them, four additional plans 
were made, in three of which the same leaf was shifted a 
distance of 2, 3 and 4 mm (one distance for each plan) in all 
beams; in the fourth plan, the leaves positions were 
randomly changed for overdosing the spinal cord. The 
intention of the four modified plans was to study the 2D-
array sensitivity to detect errors or changes. All treatments 
were computed by the treatment planning system (TPS) 
RayStation 4.0.3.4 (RaySearch Laboratories, Stockholm, 
Sweden) that uses the collapsed cone convolution algorithm. 
A linear accelerator (Elekta Synergy) was used to verify the 
SBRT treatments with 6 MV photons. 
The three 2D-arrays (PTW-Freiburg, Germany) that were used 
are: Octavius 729 with 729 ionization chambers with 
dimensions of 5x5x5 mm3 and a distance of 10 mm between 
chamber centers, Octavius 1000 SRS with smaller 977 liquid 
ionization chambers (2.3x2.3x0.5 mm3) and higher resolution 
(distance of 2.5mm between chamber centers in the central 
area and 5 mm in the outer area) and Octavius 1500 with 
1405 chambers with a size of 4.4x4.4x3 mm3 and a chamber 
